Adicet Bio, Inc. (0HX7.L)
USD 0.68
(0.39%)
USD 0.68
(0.39%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -142 Million USD | 41.35% |
| 2022 | -236.63 Million USD | 7.78% |
| 2021 | -256.6 Million USD | -309.31% |
| 2020 | -62.69 Million USD | -160.59% |
| 2019 | 103.47 Million USD | 2733.65% |
| 2018 | -3.92 Million USD | 92.64% |
| 2017 | -53.34 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -227.55 Million USD | -63.96% |
| 2024 Q2 | -204.93 Million USD | 9.94% |
| 2023 Q3 | -161.46 Million USD | 11.68% |
| 2023 FY | -138.78 Million USD | 41.35% |
| 2023 Q4 | -138.78 Million USD | 14.04% |
| 2023 Q2 | -182.81 Million USD | 12.17% |
| 2023 Q1 | -208.14 Million USD | 12.04% |
| 2022 FY | -236.63 Million USD | 7.78% |
| 2022 Q3 | -260.96 Million USD | -9.53% |
| 2022 Q2 | -238.25 Million USD | 7.4% |
| 2022 Q1 | -257.29 Million USD | -0.27% |
| 2022 Q4 | -236.63 Million USD | 9.32% |
| 2021 Q1 | -200.46 Million USD | -213.69% |
| 2021 FY | -256.6 Million USD | -309.31% |
| 2021 Q2 | -188.18 Million USD | 6.13% |
| 2021 Q4 | -256.6 Million USD | -49.45% |
| 2021 Q3 | -171.69 Million USD | 8.76% |
| 2020 Q4 | -63.9 Million USD | 24.78% |
| 2020 Q3 | -84.96 Million USD | -365.18% |
| 2020 Q2 | -18.26 Million USD | -170.9% |
| 2020 Q1 | -6.74 Million USD | 36.44% |
| 2020 FY | -62.69 Million USD | -160.59% |
| 2019 Q1 | 24.64 Million USD | 0.0% |
| 2019 FY | 103.47 Million USD | 2733.65% |
| 2019 Q4 | -10.6 Million USD | 0.0% |
| 2018 FY | -3.92 Million USD | 92.64% |
| 2017 FY | -53.34 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | -37.937% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -354.906% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 171.698% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 545.376% |
| bluebird bio, Inc. | 108.57 Million USD | 230.797% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -1475.067% |
| Imunon, Inc. | -4.69 Million USD | -2921.914% |
| Editas Medicine, Inc. | -87.11 Million USD | -63.01% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 101.105% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 106.769% |
| Myriad Genetics, Inc. | 88.1 Million USD | 261.19% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 180.095% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -323.563% |
| Verastem, Inc. | -37.27 Million USD | -280.943% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 101.724% |
| Waters Corporation | 1.96 Billion USD | 107.244% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.529% |
| Biogen Inc. | 6.28 Billion USD | 102.258% |
| Nektar Therapeutics | 210.24 Million USD | 167.546% |
| Perrigo Company plc | 3.32 Billion USD | 104.275% |
| Dynavax Technologies Corporation | 106.63 Million USD | 233.172% |
| Illumina, Inc. | 1.21 Billion USD | 111.698% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 2137.98% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | -24.691% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 197.885% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 2075.901% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 137.494% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -1900.113% |
| Evolus, Inc. | 63.7 Million USD | 322.905% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -285.849% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -424.015% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 130.959% |
| FibroGen, Inc. | 56.76 Million USD | 350.159% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 112.402% |
| OPKO Health, Inc. | 230.68 Million USD | 161.56% |
| Homology Medicines, Inc. | 18.43 Million USD | 870.234% |
| Geron Corporation | 14.76 Million USD | 1062.049% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 108.958% |
| Exelixis, Inc. | -73.05 Million USD | -94.398% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -161.737% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 5.97% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | -27.473% |
| Zoetis Inc. | 4.76 Billion USD | 102.982% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 28.932% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -1310.069% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 98.515% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -874.526% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 113.47% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 114.665% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | -4.88% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 110.284% |
| Blueprint Medicines Corporation | 702.83 Million USD | 120.205% |
| Insmed Incorporated | 721.62 Million USD | 119.679% |
| TG Therapeutics, Inc. | 17.86 Million USD | 895.029% |
| Incyte Corporation | -3.17 Billion USD | 95.527% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 118.544% |